These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 32311990

  • 1. A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis.
    He J, Lin JT.
    Medicine (Baltimore); 2020 Apr; 99(16):e19789. PubMed ID: 32311990
    [Abstract] [Full Text] [Related]

  • 2. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 3. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug 22; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J.
    Respir Res; 2017 Nov 25; 18(1):196. PubMed ID: 29178871
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
    Wang Z, Tadayasu Y, Hu N, Shu S, Hu C, Luo Z.
    Pulm Pharmacol Ther; 2020 Aug 25; 63():101944. PubMed ID: 32916296
    [Abstract] [Full Text] [Related]

  • 6. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA, Hoz A, Xue W, Ferguson GT, Miravitlles M.
    COPD; 2020 Oct 25; 17(5):477-484. PubMed ID: 32928003
    [Abstract] [Full Text] [Related]

  • 7. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
    Ichinose M, Nishimura M, Akimoto M, Kurotori Y, Zhao Y, de la Hoz A, Mishima M.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 25; 13():2147-2156. PubMed ID: 30034230
    [Abstract] [Full Text] [Related]

  • 8. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T.
    J Comp Eff Res; 2019 Nov 25; 8(15):1299-1316. PubMed ID: 31559852
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 25; 13():1407-1419. PubMed ID: 29750027
    [Abstract] [Full Text] [Related]

  • 10. Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Tashiro H, Tajiri R, Takamori A, Uchida M, Kato G, Kurihara Y, Sadamatsu H, Kinoshita T, Yoshida M, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2021 Nov 25; 16():3297-3307. PubMed ID: 34908832
    [Abstract] [Full Text] [Related]

  • 11. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun 25; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 12. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    NPJ Prim Care Respir Med; 2017 Feb 02; 27(1):7. PubMed ID: 28154373
    [Abstract] [Full Text] [Related]

  • 13. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
    Cataldo D.
    Rev Med Liege; 2016 Jun 02; 71(6):308-313. PubMed ID: 28383865
    [Abstract] [Full Text] [Related]

  • 14. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2020 Jun 02; 15():2115-2126. PubMed ID: 32982204
    [Abstract] [Full Text] [Related]

  • 15. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.
    Respir Med; 2017 Jan 02; 122():58-66. PubMed ID: 27993292
    [Abstract] [Full Text] [Related]

  • 16. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
    Maltais F, de la Hoz A, Casaburi R, O'Donnell D.
    Adv Ther; 2021 Feb 02; 38(2):835-853. PubMed ID: 33306188
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016 Feb 02; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 18. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V.
    Ther Adv Respir Dis; 2016 Oct 02; 10(5):391-401. PubMed ID: 27405723
    [Abstract] [Full Text] [Related]

  • 19. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, Amatto VC, Schmidt O, Bjermer L.
    Adv Ther; 2015 Sep 02; 32(9):809-22. PubMed ID: 26404912
    [Abstract] [Full Text] [Related]

  • 20. Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, Takizawa A, Grönke L, Hirata K.
    Adv Ther; 2017 Jul 02; 34(7):1622-1635. PubMed ID: 28537001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.